Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
Details of the panel are as follows:
Session Title: Igniting continuous support – how can industry keep the antibiotic pipeline afloat?
- Commitment from small, medium and large pharmaceutical companies to keep investing in the antibiotic field
- From push to pull incentives - what can industry do to keep driving the conversation and tangible outcomes?
- Striving in R&D, balancing risk-benefit assessments and overcoming regulatory setbacks. What is the key?
Date and time:
Dr. Stein is also the chairman of the
Antimicrobial resistance is a growing public health threat. In
As the leading conference on antimicrobial resistance, the World Antimicrobial Resistance Congress gathers key stakeholders from government, funding agencies, pharma, academia, hospitals, and payers to discuss change on both the scientific and economic sides of the antimicrobial resistance space. More information about the 2017
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, and other attributes of CD101 and CD201 and other potential product candidates, including the potential for these compounds to successfully treat or prevent infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
Robert H. Uhl Westwicke Partners, LLCManaging Director (858) 356-5932 email@example.com MEDIA CONTACT: Christy Curran Sam Brown Inc.(615) 414-8668 ChristyCurran@sambrown.com